The European Commission has granted marketing authorization for Kostaive (ARCT-154), a self-amplifying mRNA COVID-19 vaccine, ...

Global biotechnology leader CSL and sa-mRNA pioneer Arcturus Therapeutics today announced that the European Commission has granted marketing authorization for KOSTAIVE® (ARCT-154), a self-amplifying ...

Significant research news last week included a setback for Pliant Therapeutics, when it paused a Phase IIb trial of its bexotegrast in idiopathic pulmonary fibrosis (IPP). Also, US biotech AnaptysBio ...

What did ancient Greeks wear in the winter? A natural question as all statues of Greeks in antiquity depict them dressed in ...

Also in Europe, officials signed off on CSL and Arcturus Therapeutics' self-amplifying ... Ixchiq, for use in people 18 years of age and older. Late-stage trial data show the vaccine "induces ...

Because we are overdue a once-in-a-lifetime stellar event that will transfix backyard stargazers and professional astronomers ...

Across the recent three months, 5 analysts have shared their insights on Arcturus Therapeutics (NASDAQ:ARCT), expressing a variety of opinions spanning from bullish to bearish. The table below ...

UNLEASH, the world's leading event and media platform for HR innovation and excellence, and The Josh Bersin Company, the leading authority on HR, talent, and AI-driven workforce transformation, are ...

and had been driven by "tremendous patient satisfaction and the visible results that people experience." Mounjaro was approved by the FDA in May, becoming the first combined GLP-1/GIP agonist to ...

When most people think about investing in the stock market, they imagine blue-chip corporations like Amazon.com and Apple. However, you don’t need to have thousands of dollars in the bank to get ...

If you're interested in exploring more stocks under $20 get an edge over other traders with Benzinga Pro while we're currently offering a 14-day trial. Stocks under $20 offer investors and ...

Teliso-V (telisotuzumab vedotin) is pitching to become the first targeted cancer treatment for people with non-small cell lung cancer (NSCLC) whose tumours overexpress c-Met. The c-Met protein ...